10 results
Primary objective- To explore the pharmacodynamic effects of topically applied IMQ (in combination with or without TS) - To identify dose-response relationship of topically applied IMQ Secondary objective- To assess safety and tolerability of…
To evaluate patient related outcomes mainly quality of life and treatment satisfaction. Side effects and therapy adherence were also evaluated because these can interfere with quality of life and treatment satisfaction.
Primary objective: * Examine the safety and tolerability, both local and general, of ProCervix Solution (escalating doses) and ProCervix Powder in women infected by HPV 16 and/or 18 with normal cytology from Week 0 to Week 10. Secondary objectives…
Primary objectives: 1. To assess the effect of experimental immunization with GA2 sporozoites by mosquito bite with and without co-administration of different adjuvants on the pre-patent period after controlled human malaria infection (CHMI).2. To…
Primary objective: To compare long-term efficacy of curettage prior to IMQ 5% cream (Aldara®) therapy versus standard surgical excision in primary nBCC.Secondary objective: To assess compliance, pain, cosmetic outcomes, patient satisfaction, patient…
The aim of this study is to assess the safety and tolerability of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis.
To assess the short-term efficacy of stellate ganglion block on hot flush reduction versus sham procedure
Primary* To immunologically characterize imiquimod-induced inflammation after 7-day exposure of healthy skin;* To evaluate local complement activation/depositions after a prolonged topical imiquimod challenge;* To evaluate systemic activation of…
Primary ObjectiveTo explore the pharmacodynamics effects of topically applied OMN ono Tape-stripped skin of healthy volunteerso Tape-stripped and IMQ-primed skin of healthy volunteerso Tape-stripped skin prior to IMQ applicationSecondary Objectives…
The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF.